Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma

Sakaguchi, Yoshihisa; Komori, Takaya; Aoki, Megumi; Otsuka, Atsushi; Kabashima, Kenji; Matsushita, Satoru

doi:10.2340/00015555-3681

Cited by 5 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vandetanib is potentially associated with severe phototoxic reaction as well as more specific UVinduced reactions, including photo onycholysis or progressive hyperpigmentation and blue dots. 69,74,75 Photosensitivity has been reported occasionally with immune checkpoint inhibitors, including the PD-1 (programmed cell death protein 1) inhibitor nivolumab, 69,76,77 and the anti -CTLA-4 (cytotoxic T lymphocyte-associated protein 4) antibody ipilimumab. 78,79 More importantly, patients with melanoma treated with anti PD-1, PD-L1 and, less frequently, anti-CTLA-A may develop vitiligo-like lesions, which occur in up to 11% of patients with metastatic melanoma.…”

Section: A N Tica Ncer Tr E Atm E N Ts a N D Cu Ta N Eous Photose Nsi...mentioning

confidence: 99%

“…Photosensitivity has been reported occasionally with immune checkpoint inhibitors, including the PD‐1 (programmed cell death protein 1) inhibitor nivolumab, 69,76,77 and the anti ‐CTLA‐4 (cytotoxic T lymphocyte‐associated protein 4) antibody ipilimumab 78,79 . More importantly, patients with melanoma treated with anti PD‐1, PD‐L1 and, less frequently, anti‐CTLA‐A may develop vitiligo‐like lesions, which occur in up to 11% of patients with metastatic melanoma 78 .…”

Section: Anticancer Treatments and Cutaneous Photosensitivitymentioning

confidence: 99%

See 1 more Smart Citation

Photoprotection: Current developments and controversies

Pellacani,

Lim,

Stockfleth

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

This review aimed at summarizing some of the key points that were discussed during the photoprotection session at the International Forum of Dermatology in 2022. This international conference was designed to address prominent topics of clinical dermatology in a holistic way, allowing to articulate multiple viewpoints. Therefore, this review does not claim to be exhaustive, but is instead intended to give an overview of recent developments and ongoing controversies in the field of photoprotection. Cumulative ultraviolet radiation (UVR) exposure is the major aetiological factor in the development of photoageing, photoimunosuppression and photocarcinogenesis. UVA (320–400 nm) penetrates into the dermis and damages DNA and other intracellular and acellular targets primarily by generating reactive oxygen species (ROS). It is the major contributor to photoageing, characterized by fine and coarse wrinkles, dyspigmentation and loss of elasticity. UVB (290–320 nm) is responsible for sunburns through direct damage to DNA by the formation of 6–4 cyclobutane pyrimidine dimers (CPDs) and pyrimidine 6–4 pyrimidone photoproducts. Both UVA and UVB exposure increase the risk of basal cell carcinoma, squamous cell carcinoma and melanoma. In recent years, visible light (VL; 400–700 nm) has also been implicated in the exacerbation of conditions aggravated by sun exposure such as hyperpigmentation and melasma. Photoprotection is a critical health strategy to reduce the deleterious effects of UVR and VL. Comprehensive photoprotection strategies include staying in the shade when outdoors, wearing photoprotective clothing including a wide‐brimmed hat, and sunglasses, and the use of sunscreen. Due to the absorption of UV filters, the safety of sunscreens has been questioned. Newer sunscreens are becoming available with filters with absorption even beyond the UV spectrum, offering enhanced protection compared with older products. Prevention of photocarcinogenesis, sun‐induced or sunlight‐exacerbated hyperpigmentary conditions and drug‐induced photosensitivity is an important reason for adopting comprehensive photoprotection strategies.

show abstract

Section: A N Tica Ncer Tr E Atm E N Ts a N D Cu Ta N Eous Photose Nsi...mentioning

confidence: 99%

Section: Anticancer Treatments and Cutaneous Photosensitivitymentioning

confidence: 99%

Photoprotection: Current developments and controversies

Pellacani,

Lim,

Stockfleth

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Dermatologic toxicities appear to be amongst the most common immune‐related AEs associated with immune checkpoint inhibitors (ICIs) 46 . Overall, the anti‐PD‐1 nivolumab has been associated with an all‐grade incidence of photosensitivity estimated at 1.5% (95% CI: 0.5%–4.4%) 7,47 …”

Section: Photosensitivity and Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…46 Overall, the anti-PD-1 nivolumab has been associated with an all-grade incidence of photosensitivity estimated at 1.5% (95% CI: 0.5%-4.4%). 7,47 Moreover, a progressive vitiligo-like skin hypopigmentation may occur. These pigmentary changes have been reported in almost all cases in patients treated for melanoma with anti-PD-1 agents, with an overall incidence of 7%-8%.…”

Section: Photosensitivity and Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Anticancer treatments and photosensitivity

Sibaud

2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Drug‐induced photosensitivity is associated with a wide range of anticancer treatments, including conventional chemotherapeutic agents, targeted anticancer therapies, and immune checkpoint inhibitors. These dermatologic adverse events can have a major impact on the well‐being and quality of life of cancer patients, leading to dose modifications and interruption or discontinuation of anticancer treatments in severe cases. However, the heterogeneous nature of the photosensitive reactions induced by these agents, as well as the common concomitant use of other potentially photosensitizing drugs (antibiotics, voriconazole, nonsteroidal anti‐inflammatory drugs, etc.), can make the diagnosis and, therefore the prevention, of these adverse events particularly challenging. The aim of this review is to describe the most characteristic forms of photosensitivity observed in patients being treated with anticancer treatments, including phototoxicity and photoallergy, and other potentially photo‐induced manifestations such as UV recall, exaggerated sunburn reactions associated with treatment‐related vitiligo, drug‐induced cutaneous lupus erythematosus, and UV‐induced hyperpigmentation. We also discuss the photosensitive reactions recently reported with new‐generation targeted anticancer therapies and immune checkpoint inhibitors and highlight the importance of continued surveillance to identify photosensitizing agents, and of educating patients on the need for preventive UVA/UVB photoprotective measures.

show abstract

“…2 The brake of skin tolerance exacerbates excessive inflammatory reactions, 3 and ICI treatment impairs skin tolerance mechanisms. 4,5 Indeed, skin toxicities are one of the most common immune checkpoint inhibitor-related adverse events (irAE), such as maculopapular rashes, lichenoid dermatitis, bullous pemphigus, and vitiligo. 6 Psoriasis has also been reported as a rare irAE in both the exacerbation of pre-existing psoriasis and the novel onset psoriasis during immunotherapy.…”

Section: O R R E S P O N D E N C E Exacerbation Of Pre-existence Psor...mentioning

confidence: 99%